Isabelle Dufresne
No más puestos en curso
Historial de carrera de Isabelle Dufresne
Antiguos cargos conocidos de Isabelle Dufresne.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Gestion Fonds InnovExport Commandité inc
Gestion Fonds InnovExport Commandité inc Investment ManagersFinance Gestion Fonds InnovExport Commandité inc (Fonds Innovexport) is a venture capital firm founded in 2016. The firm is headquartered in Quebec, Canada. | Inversor de Capital Privado | 01/07/2019 | 01/03/2022 |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Director/Miembro de la Junta | 09/07/2009 | 09/09/2013 |
Chlorion Pharma, Inc.
Chlorion Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Chlorion Pharma, Inc. Develops small molecule leads for the treatment of naturopathic pain and epilepsy. It develops therapeutics for the treatment of neuropathic pain and epilepsy. The company was founded by Jeffrey A. M. Coull, Yves De Koninck and Martin Gagnon in 2004 and is headquartered in Laval, Canada. | Director/Miembro de la Junta | - | - |
Gestion Bio Innovation, Inc.
Gestion Bio Innovation, Inc. Investment ManagersFinance Gestion Bio Innovation Inc (Gestion Bio Innovation) is a venture capital subsidiary of Centre Québécois de Valorisation des Biotechnologies founded in 1900. The firm is headquartered in Quebec, Canada. | Director de Investigación - Acciones | - | - |
Analista de Capital Privado | - | 25/06/2009 | |
Inversor de Capital Privado | - | - |
Formación de Isabelle Dufresne.
Université Laval | Graduate Degree |
University of Quebec | Undergraduate Degree |
Estadísticas
Internacional
Canadá | 7 |
Operativa
Private Equity Investor | 2 |
Director/Board Member | 2 |
Director of Research - Equity | 1 |
Sectorial
Finance | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 4 |
---|---|
Gestion Bio Innovation, Inc.
Gestion Bio Innovation, Inc. Investment ManagersFinance Gestion Bio Innovation Inc (Gestion Bio Innovation) is a venture capital subsidiary of Centre Québécois de Valorisation des Biotechnologies founded in 1900. The firm is headquartered in Quebec, Canada. | Finance |
Chlorion Pharma, Inc.
Chlorion Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Chlorion Pharma, Inc. Develops small molecule leads for the treatment of naturopathic pain and epilepsy. It develops therapeutics for the treatment of neuropathic pain and epilepsy. The company was founded by Jeffrey A. M. Coull, Yves De Koninck and Martin Gagnon in 2004 and is headquartered in Laval, Canada. | Commercial Services |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
Gestion Fonds InnovExport Commandité inc
Gestion Fonds InnovExport Commandité inc Investment ManagersFinance Gestion Fonds InnovExport Commandité inc (Fonds Innovexport) is a venture capital firm founded in 2016. The firm is headquartered in Quebec, Canada. | Finance |
- Bolsa de valores
- Insiders
- Isabelle Dufresne
- Experiencia